Tag Archives: AACE

Screening for fatty liver disease in patients with diabetes is no longer limited to identifying elevated liver enzymes or calculating a fibrosis score during an annual visit. Instead, clinicians are entering an era where diabetes care and hepatology increasingly overlap, especially as metabolic dysfunction-associated steatotic liver disease, or MASLD, becomes …

Read More »